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        Introduction 
  Vascular remodeling requires a complex interplay between 
growth factor receptors, extracellular matrix components, 
and integrin receptors, making these attractive targets for anti-
angiogenic therapy. Key intermediary proteins function in a 
membrane-proximal manner to integrate extracellular sig-
nals and promote intracellular signal transduction required 
for vasculogenesis and angiogenesis. One of these intra-
cellular proteins is the cytoplasmic tyrosine kinase FAK, which 
is activated by growth factor receptors or integrin clustering 
and is critical for the assembly of a variety of signaling com-
plexes (  Mitra and Schlaepfer, 2006  ). FAK expression is es-
sential for blood vessel development because global (  Ilic 
et al., 1995  ) or endothelial cell (EC)-specifi  c (  Shen et al., 2005 ; 
  Braren et al., 2006  ) knockout of FAK results in embryonic 
lethality with vascular defects. Interestingly, overexpression 
of FAK has the opposite effect, as transgenic mice over-
expressing FAK in ECs show enhanced angiogenic responses 
to skin wounds and muscle ischemia (  Peng et al., 2004  ). 
Together, these studies point to FAK as a critical factor for 
developmental and pathological angiogenesis. Indeed, con-
trol of FAK signaling has been suggested as a potential anti    -
cancer therapy and several FAK inhibitors have recently been 
developed (  Slack-Davis et al., 2007  ;   Roberts et al., 2008  ). 
However, it is not clear whether FAK inhibitors target ECs or 
impact angiogenesis directly. 
  Because conditional knockout of FAK from the endo-
thelium produces a lethal phenotype, the role of FAK during 
vascular remodeling in vivo has not been fully addressed. 
Here, we report that tamoxifen-inducible, Cre-mediated FAK 
deletion from adult endothelium is surprisingly not lethal 
due to functional compensation by the FAK-related protein 
proline-rich tyrosine kinase 2 (Pyk2). This compensatory 
switch from FAK to Pyk2 occurs in blood vessels and in 
cultured human ECs, promoting vascular hemostasis and 
preserving integrin-mediated signaling during vascular re-
modeling events. 
F
ocal adhesion kinase (FAK) plays a critical role dur-
ing vascular development because knockout of 
FAK in endothelial cells (ECs) is embryonic lethal. 
Surprisingly, tamoxifen-inducible conditional knockout of 
FAK in adult blood vessels (inducible EC  –  speciﬁ  c  FAK 
knockout [i-EC-FAK-KO]) produces no vascular pheno-
type, and these animals are capable of developing a 
robust growth factor  –  induced angiogenic response. 
Although angiogenesis in wild-type mice is suppressed by 
pharmacological inhibition of FAK, i-EC-FAK-KO mice 
are refractory to this treatment, which suggests that adult 
i-EC-FAK-KO mice develop a compensatory mechanism 
to bypass the requirement for FAK. Indeed, expression of 
the FAK-related proline-rich tyrosine kinase 2 (Pyk2) is 
elevated and phosphorylated in i-EC-FAK-KO blood ves-
sels. In cultured ECs, FAK knockdown leads to increased 
Pyk2 expression and, surprisingly, FAK kinase inhibition 
leads to increased Pyk2 phosphorylation. Pyk2 can func-
tionally compensate for the loss of FAK because knock-
down or pharmacological inhibition of Pyk2 disrupts 
angiogenesis in i-EC-FAK-KO mice. These studies reveal 
the adaptive capacity of ECs to switch to Pyk2-dependent 
signaling after deletion or kinase inhibition of FAK.
  Compensatory role for Pyk2 during angiogenesis 
in adult mice lacking endothelial cell FAK 
    Sara M.     Weis  ,   
1       Ssang-Taek     Lim  ,   
1       Kimberly M.     Lutu-Fuga  ,   
1       Leo A.     Barnes  ,   
1       Xiao Lei     Chen  ,   
1       Joachim R.     G  ö  thert  ,   
4     
  Tang-Long     Shen  ,   
5,6       Jun-Lin     Guan  ,   
4,5       David D.     Schlaepfer  ,   
1,2     and   David A.     Cheresh     
1,3     
   
1  Moores UCSD Cancer Center,  
2  Department of Reproductive Medicine, and  
3  Department of Pathology, University of California, San Diego, La Jolla, CA 92093 
   
4  Department of Hematology, University Hospital of Essen, Essen 45122, Germany 
   
5  Department of Internal Medicine and  
6  Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI 48109     JCB • VOLUME 181 • NUMBER 1 • 2008  44
  Robust angiogenic response in 
i-EC-FAK-KO mice 
  In contrast to previous EC-specifi  c FAK knockout models with 
embryonic lethality (  Shen et al., 2005  ;   Braren et al., 2006  ), 
knockout of FAK in adult endothelium did not produce an overt 
phenotype in mice of either gender. This fi  nding prompted us to 
challenge these mice with angiogenic growth factors to assess 
the role of FAK during angiogenesis. Matrigel containing basic 
fi  broblast growth factor (bFGF) or VEGF was implanted sub-
cutaneously into mice to induce neovascularization. After 5 d, 
mice were injected with FITC-lectin to label ECs and the plugs 
were removed and homogenized to quantify the FITC-lectin 
content. Surprisingly, either bFGF or VEGF elicited a robust 
angiogenic response in i-EC-FAK-KO mice that was equivalent 
to or greater than that observed in WT mice (  Fig. 1 A  ). Although 
neovascularization was evident by both EC-specifi  c FITC-lectin 
binding and labeling with EC markers, vessels within i-EC-FAK-
KO plugs did not stain positive for FAK (  Fig. 1 B  ). This result 
  Results and discussion 
  Generation of mice with inducible, 
conditional FAK knockout 
  To assess the postdevelopmental role of FAK in adult blood 
vessels, we used a Cre/loxP strategy to create an inducible, 
conditional knockout of FAK in ECs. Floxed FAK mice con-
taining two loxP sites fl  anking exon 3 of the FAK gene (  Shen 
et al., 2005  ) were crossed with End-SCL-Cre-ER(T) mice 
containing tamoxifen-inducible Cre-ER(T) driven by the 5    
endothelial enhancer of the stem cell leukemia locus (  Gothert 
et al., 2004  ). At 5 wk of age, littermates of FAK fl  /fl  ;Cre(+) 
and FAK fl  /fl  ;Cre(    ) mice were treated with 2 mg tamoxifen 
every 2 d for 2 wk to generate   “  wild-type  ”   (WT) mice (tamoxifen-
treated mice with no Cre expression and thus no FAK deletion) 
and inducible EC  –  specifi   c  FAK  knockout  ( “ i-EC-FAK-KO ” ) 
mice (tamoxifen-induced EC-specifi  c Cre expression result-
ing in FAK deletion). 
  Figure 1.       Robust growth factor  –  induced angiogenesis in i-EC-FAK-KO mice.   Matrigel containing PBS, bFGF, or VEGF was injected subcutaneously to 
assess angiogenesis in vivo. (A) Angiogenic responses to bFGF or VEGF were equal or more robust in i-EC-FAK-KO compared with the WT, quantiﬁ  ed 
by FITC-lectin content.   n   = 7  –  15 each. (B, left) FITC-lectin  –  perfused blood vessels within Matrigel from the WT and i-EC-FAK-KO appear similar. Bar, 50   μ  m. 
(right) Staining for FAK (red) and EC markers (green) conﬁ  rms the lack of FAK on i-EC-FAK-KO vessels. Bar, 5   μ  m. (C) Hemoglobin concentration is 
increased in i-EC-FAK-KO plugs, which is consistent with their bloodier appearance.   n   = 4 each. (D) i-EC-FAK-KO mice showed 30% less VEGF-induced 
leakage in the skin compared with the WT, which suggests that their robust angiogenic response was not caused by increased leakage.   n   = 11 each. 
(E) Treatment with the NVP-TAC544 FAK inhibitor blocked the angiogenic response induced by bFGF in WT but not i-EC-FAK-KO.   n   = 4 each; *, P   <   0.05 
versus vehicle. All graphs show mean   ±   SEM.     45 PYK2 COMPENSATES FOR LOSS OF FAK IN BLOOD VESSELS   •   WEIS ET AL.
is expressed selectively on angiogenic EC in vivo (  Brooks et al., 
1994  ) and inhibitors of    v   3 abolish angiogenesis in response to 
growth factors or tumors (  Brooks et al., 1995  ), we examined the 
role of this integrin during angiogenesis in the presence or ab-
sence of FAK. In Matrigel plugs from WT and i-EC-FAK-KO 
mice, bFGF-stimulated blood vessels showed intense    v  3 
staining, indicating that FAK is not required for    v  3  expression 
on angiogenic EC (  Fig. 2 A  ). To assess the effi  cacy of    v  3  an-
tagonism, Matrigel plugs were implanted containing bFGF along 
with a cyclic RGD-fK peptide that selectively blocks    v  3  func-
tion (  Dai et al., 2000  ) or a control cyclic RAD-fK peptide. 
We found that the cRGD-fK peptide blocked angiogenesis in 
both genotypes (  Fig. 2 B  ), which suggests that integrin-mediated 
signals can be transmitted through alternative intracellular com-
ponents during angiogenesis in the absence of EC FAK. 
  Pyk2 expression is increased on normal 
and angiogenic blood vessels in 
i-EC-FAK-KO mice 
  Pyk2 is a cytoplasmic tyrosine kinase structurally related to 
FAK. FAK and Pyk2 have been proposed to promote both dis-
tinct and overlapping signaling events, which appear to vary 
by cell type. Although FAK is ubiquitously expressed, Pyk2 is 
selectively enriched in certain cell types, including hemato-
poietic cells (  Tang et al., 2002  ). Although Pyk2 has recently 
been linked to EC functions including VE-cadherin  –  mediated 
adhesion (  van Buul et al., 2005  ;   Allingham et al., 2007  ), cell 
migration (  Avraham et al., 2003  ), angiogenic sprouting (  Tang 
et al., 2002  ;   Matsui et al., 2007  ), and integrin-mediated signal-
ing (  Lamalice et al., 2007  ), the role of Pyk2 during vascular 
remodeling in vivo remains poorly understood. Although Pyk2 
expression is enhanced in embryonic fi  broblasts isolated from 
FAK null mice (  Sieg et al., 1998  ), no changes in Pyk2 levels 
have been detected within tissues from conditional FAK knock-
out mice with the exception of conditional knockout in osteo-
blasts (  Kim et al., 2007  ). 
  To determine if Pyk2 may account for the compensatory 
angiogenic response observed in adult i-EC-FAK-KO mice, tis-
sues from WT or i-EC-FAK-KO mice were examined using 
confi  rms the loss of EC FAK expression in i-EC-FAK-KO 
mice and specifi  cally on the newly forming vessels within the 
Matrigel plugs. The Matrigel plugs from i-EC-FAK-KO mice 
appeared bloodier and had a higher hemoglobin concentration 
than the WT (  Fig. 1, B and C  ). However, local VEGF injec-
tion to the skin induced a slightly lower vascular leak response 
in i-EC-FAK-KO mice (  Fig. 1 D  ). Thus, the more robust angio-
genic response in i-EC-FAK-KO mice does not appear to be a 
function of VEGF-induced vascular leak. 
  Antiangiogenic activity of a FAK 
kinase inhibitor 
  Small molecule FAK kinase inhibitors can suppress tumor cell 
proliferation and as such are now undergoing clinical evalua-
tion as anticancer drugs (  Shi et al., 2007  ;   Slack-Davis et al., 
2007  ). In addition to direct effects on tumor cells, it is not known 
whether these inhibitors also suppress angiogenesis by target-
ing FAK activity in ECs, pericytes, infl  ammatory cells, or stro-
mal cells. Here, we report that daily treatment with a FAK 
kinase inhibitor (NVP-TAC544; Fig. S1, available at http://www
.jcb.org/cgi/content/full/jcb.200710038/DC1) in WT mice re-
sulted in an 80% decrease in bFGF-mediated angiogenesis but 
had no effect in i-EC-FAK-KO mice (  Fig. 1 E  ). Because this 
ATP-competitive inhibitor blocks FAK kinase activity in all 
cell types involved in the angiogenic response, our results in-
dicate that FAK kinase activity specifi  cally within ECs is criti-
cal for angiogenesis in WT animals and that targeting FAK 
in ECs accounts for the antiangiogenic activity of this drug. 
Thus, a compensatory signaling pathway in ECs may be oper-
ative accounting for a FAK-independent angiogenic response 
in i-EC-FAK-KO mice. 
  Angiogenesis is integrin-dependent in 
i-EC-FAK-KO mice 
  Because integrins do not possess intrinsic enzymatic activity, 
signal transduction requires association with and activation of 
membrane-proximal proteins such as FAK, which transmits sig-
nals from integrins and initiates intracellular signaling pathways 
(  van Nimwegen and van de Water, 2007  ). Because integrin    v  3 
  Figure 2.       Integrin requirement for angiogen-
esis despite loss of EC FAK expression.   (A)     3 
integrin (blue) is expressed on vessels (green) 
within Matrigel plugs from WT or i-EC-FAK-KO 
mice. Bar, 5   μ  m. (B) The selective     v    3 integrin 
antagonist cRGD-fK blocked the angiogenic 
response equivalently for both genotypes.   n   = 
4 each group; *, P   <   0.05 versus bFGF. Graph 
shows mean   ±   SEM.     JCB • VOLUME 181 • NUMBER 1 • 2008  46
ing of a more robust angiogenic response in i-EC-FAK-KO mice 
(  Fig. 1  ). To investigate signaling within angiogenic tissues di-
rectly, Matrigel plugs were lysed and processed for immuno-
blotting. The cells infi  ltrating the Matrigel plugs growing within 
i-EC-FAK-KO mice showed decreased FAK along with in-
creased Pyk2 expression and pY402 phosphorylation compared 
with the WT (  Fig. 3 D  ). Together, our results suggest that Pyk2 
expression increases after the loss of FAK on blood vessels in 
vivo. This Pyk2 response appears to be an overcompensation 
resulting in robust angiogenesis and vascular leakage, possibly 
because of constitutively increased Pyk2 activity. 
  Pyk2 compensation for loss of FAK also 
occurs in human ECs 
  To investigate whether a similar compensatory mechanism might 
take place in human ECs, we knocked down FAK in primary 
human umbilical vein ECs (HUVECs) using short hairpin RNA 
(shRNA) and monitored expression of Pyk2 over time. Compared 
with a nonsilencing scramble control shRNA (Scr), FAK shRNA 
immunohistochemistry (  Fig. 3 A  ). As expected, FAK was ubiq-
uitously expressed on all cell types in the heart (unpublished 
data). In contrast, we found expression of FAK pY861 to be pri-
marily associated with vascular structures in the WT heart, and 
this was reduced in the i-EC-FAK-KO heart (  Fig. 3, A and B  ). 
Pyk2 expression in the WT heart was primarily restricted to 
lymphatic vessels and hematopoietic cells and was minimally 
detected on ECs (  Fig. 3, A and B  ). In contrast, we observed a 
10-fold increase in the percentage of Pyk2-positive ECs within 
i-EC-FAK-KO mice (  Fig. 3 B  ). We confi  rmed this increase in 
Pyk2 expression and activated Pyk2 phosphorylated at Y402 by 
immunoblotting mouse hearts lysates (  Fig. 3 C  ). Pyk2 may be 
constitutively active in these tissues because we also measured 
elevated phosphorylation of the FAK/Pyk2 substrates Src 
pY418, p130Cas pY249/pY410, and paxillin pY118 (  Wu et al., 
2008  ). These substrates downstream of integrin ligation and 
FAK activation play a role in cell migration and invasion during 
angiogenesis and tissue remodeling ( Mitra and Schlaepfer, 2006 ). 
Increased phosphorylation of these substrates supports our fi  nd-
  Figure 3.       Pyk2 is up-regulated in the absence of FAK.   (A and B) FAK pY861 staining (a marker for activated FAK) appears on blood vessels in the WT but 
not i-EC-FAK-KO heart. Although minimally detected on blood vessels in the WT heart, Pyk2 expression on ECs is elevated in i-EC-FAK-KO. Graph repre-
sents mean   ±   SEM. Bar, 10   μ  m. (C) Expression of Pyk2, phosphorylation of Pyk2 on its autophosphorylation site Y402, and phosphorylation of FAK/Pyk2 
substrates was increased 3- to 10-fold in heart lysates from i-EC-FAK-KO mice. (D) Pyk2 and pY402 were elevated in angiogenic Matrigel plugs from i-EC-
FAK-KO mice. (E) Primary human ECs (HUVECs) were treated with shRNA for FAK or a nonsilencing scramble shRNA control   “  Scr.  ”   Pyk2 expression was 
elevated after FAK deletion. (F) BAECs treated with the NVP-TAC544 FAK inhibitor for 1 h showed dose-dependent FAK blockade (pY397) and a surprising 
increase in Pyk2 (pY402) phosphorylation.     47 PYK2 COMPENSATES FOR LOSS OF FAK IN BLOOD VESSELS   •   WEIS ET AL.
jcb.200710038/DC1). Together, our in vitro and in vivo studies 
using genetic and pharmacological approaches suggest that Pyk2 
activity increases upon FAK deletion or inhibition and that a 
balance of FAK/Pyk2 activity may infl  uence EC growth or sur-
vival during angiogenesis. 
  Pyk2 can functionally compensate for loss 
of FAK during angiogenesis 
  To further manipulate FAK and Pyk2 function during angio-
genesis, we grew sections of mouse aorta in a 3D Matrigel culture 
to examine EC sprouting over time. Consistent with our in vivo 
results (  Fig. 1  ), we observed equivalent ex vivo sprouting be-
tween genotypes, and immunohistochemical staining confi  rmed 
the absence of FAK on ECs sprouting from i-EC-FAK-KO ex-
plants (  Fig. 4  ). If Pyk2 does compensate for FAK deletion, then 
a Pyk2 blockade should impair the angiogenic response in 
i-EC-FAK-KO mice. To test this using a knockdown approach, 
aortic rings were cultured in the presence of lentiviruses ex-
pressing GFP along with shRNA for FAK, Pyk2, or a scrambled 
control. Immunoblotting confi  rmed equivalent GFP expression 
and shRNA-mediated knockdown (Fig. S3, available at http://
www.jcb.org/cgi/content/full/jcb.200710038/DC1), and the 
scramble control shRNA did not affect the angiogenic response 
(not depicted). In WT aortic rings, shRNA-mediated knock-
down of FAK reduced sprouting but knockdown of Pyk2 had no 
induced an 85  –  90% knockdown of FAK along with a threefold 
induction of Pyk2 expression at 7 d (  Fig. 3 E  ). These fi  ndings are 
consistent with the increase in Pyk2 we observed in i-EC-FAK-
KO mice, a model in which Cre-mediated FAK deletion occurs 
gradually during a 2-wk tamoxifen treatment period. The fact that 
compensatory Pyk2 expression increases only after 3  –  7 d may 
explain the lethality associated with EC FAK deletion during 
development ( Shen et al., 2005 ;  Braren et al., 2006 ), a situation in 
which the loss FAK cannot be compensated for by Pyk2 on a time-
scale to allow embryonic survival. 
  FAK inhibition activates Pyk2 
  Typical ECs express low levels of Pyk2, as observed for the 
mouse heart (  Fig. 3, A  –  C  ) and HUVECs (  Fig. 3 E  ). In contrast, 
bovine aortic ECs (BAECs) express signifi  cant levels of endog-
enous Pyk2 (  Fig. 3 F  ). Treatment of these Pyk2-positive ECs 
with the NVP-TAC544 FAK inhibitor induced a dose-dependent 
decrease in FAK pY397 phosphorylation along with a surpris-
ing increase in Pyk2 pY402 phosphorylation (  Fig. 3 F  ). In vitro 
kinase assays confi  rm that this inhibitor blocks FAK while in-
creasing Pyk2 in BAECs (Fig. S1 C). Although it is possible 
that this inhibitor may interact with Pyk2, leading to its activa-
tion, we observed similar Pyk2 activation in mouse embryonic 
fi  broblasts treated with two chemically distinct FAK inhibi-
tors (Fig. S2, available at http://www.jcb.org/cgi/content/full/
  Figure 4.       Ex vivo sprouting of aortic explants is normal in i-EC-FAK-KO mice.   (A and B) Aortic ring explants from WT and i-EC-FAK-KO mice were grown 
as ex vivo cultures to assess sprouting. The mean sprout length at several time points was similar between genotypes, suggesting a normal angiogenic 
response to serum.   n   = 6 each; Graph shows mean   ±   SEM. (C) Immunohistochemical staining for FAK (red) and EC (green) conﬁ  rms lack of FAK protein 
expression on vessels sprouting from rings isolated from i-EC-FAK-KO mice. Bars: (A) 0.5 mm; (C) 80   μ  m.     JCB • VOLUME 181 • NUMBER 1 • 2008  48
selective FAK deletion within ECs. The shRNA-mediated FAK 
knockdown results are consistent with our observations for 
sprouting in vivo (  Fig. 1 E  ), in which pharmacological FAK in-
hibition delivered to all cell types did not negatively affect the 
angiogenic response in i-EC-FAK-KO mice. Together, these 
studies strongly suggest that EC FAK expression is responsible 
for the antiangiogenic properties of FAK inhibitors in WT mice, 
whereas Pyk2 expression is responsible for angiogenesis in i-EC-
FAK-KO mice. 
  To further test this, aortic explants were treated daily with 
an ATP-competitive inhibitor selective for FAK but not Pyk2 
(PF-228;   Slack-Davis et al., 2007  ) or a dual inhibitor of FAK/
Pyk2 (PF-271;   Roberts et al., 2008  ). The effects of these inhibi-
tors on FAK and Pyk2 tyrosine phosphorylation are shown in 
Fig. S2. In aortic vessels isolated from WT mice, both inhibitors 
reduced the amount of angiogenic sprouting to a similar extent 
(  Fig. 5 C  ). However, only the dual FAK/Pyk2 inhibitor could 
effect, confi  rming that FAK (and not Pyk2) plays a primary role 
in angiogenesis within normal blood vessels (  Fig. 5, A and B  ). 
In i-EC-FAK-KO vessels, knockdown of FAK had no effect but 
knockdown of Pyk2 disrupted sprouting (  Fig. 5, A and B  ). 
  In the knockout mouse tissues, FAK is deleted and Pyk2 is 
up-regulated for the duration of the experiment; thus, the initial 
sprouting and invasion into the Matrigel matrix in vivo (  Fig. 1  ) 
or in vitro (  Fig. 4  ) must occur in the absence of FAK. In con-
trast, for shRNA-mediated FAK knockdown, FAK expression 
gradually decreases and compensatory Pyk2 expression gradu-
ally increases after several days as we observed for cultured 
ECs (  Fig. 3 E  ). Accordingly, in aortic sprouting experiments us-
ing shRNA-mediated FAK knockdown, we found the largest 
differences between groups between 4 and 7 d, after which time 
the rate of sprouting was equivalent (unpublished data). Another 
signifi  cant difference between these models is the fact that 
shRNA impacts all cell types, whereas the knockout mouse has 
  Figure 5.       Pyk2 can functionally compensate for loss of FAK during angiogenesis.   (A and B) Knockdown of FAK (but not Pyk2) slowed the rate of sprouting 
in WT aortic explants, indicating FAK plays the primary role during angiogenesis in normal blood vessels. For i-EC-FAK-KO, knockdown of Pyk2 (but not 
FAK) inhibited the angiogenic response. Broken lines indicate sprout length. Bar, 0.25 mm. (C) Sprouting of WT aortic explants was dose-dependently 
blocked by either a pharmacological inhibitor selective for FAK (PF-228) or a dual FAK/Pyk2 inhibitor (PF-271). Only the dual FAK/Pyk2 inhibitor (PF-271) 
blocked sprouting in i-EC-FAK-KO explants.   n   = 6 each; *, P   <   0.05 versus control shRNA or vehicle. Graphs show mean   ±   SEM. (D) Our results suggest 
a necessity for FAK and/or Pyk2 expression in ECs that can preserve the angiogenic response in i-EC-FAK-KO mice.     49 PYK2 COMPENSATES FOR LOSS OF FAK IN BLOOD VESSELS   •   WEIS ET AL.
and Sigma-Aldrich (actin). Blood vessels were labeled for   “  EC markers  ”   with 
a mix of rat anti  –  mouse antibodies recognizing Flk-1 (BD Biosciences), CD31 
(BD Biosciences), VE-cadherin (BD Biosciences), and CD105 (Millipore). 
  In vivo angiogenesis 
  The Matrigel assay was performed to assess in vivo angiogenesis (  Weis, 
2007  ). In brief, mice were injected subcutaneously on the ﬂ  ank with 400   μ  l 
growth factor  –  reduced Matrigel (BD Biosciences) containing either sterile sa-
line or 400 ng of human recombinant bFGF (Millipore) or VEGF (PeproTech). 
After 7 d, mice were injected intravenously with 20   μ  g FITC-conjugated lec-
tin that binds selectively to mouse ECs (GSL I  –  BSL I; Vector Laboratories). 
The Matrigel plugs were removed, photographed, viewed whole-mount, and 
then ﬁ  xed and stained for microscopy. Alternatively, plugs were homo  g-
enized and the ﬂ  uorescence content was read at 620 nm (Tecan) or hemo-
globin content was quantiﬁ  ed using the QuantiChrom hemoglobin assay kit 
(BioAssay Systems). 
  In vivo permeability 
  A modiﬁ  ed Miles assay was used to evaluate VEGF-induced leak in the 
skin as described previously (  Eliceiri et al., 1999  ). 
  Ex vivo angiogenesis 
  The abdominal aorta was isolated using sterile technique and cut into 
1-mm sections that were embedded in growth factor  –  reduced Matrigel and 
cultured using DME with 10% FCS and 30 ng/ml human recombinant 
VEGFA-165 (PeproTech) daily. Images were acquired on an inverted micro-
scope (Axiovert 100; Carl Zeiss, Inc.) using a 20  ×   0.70 NA objective 
(Carl Zeiss, Inc.) and a SPOT RT camera (Model 2.2.1; Diagnostic Instru-
ments, Inc.). Image J (National Institutes of Health) was used to measure 
sprout length. 
  Immunoblotting and immunostaining 
  Standard Western blotting and immunostaining of cells, whole-mount prepa-
rations, or frozen sections was performed. Secondary antibodies conjugated 
to Alexa Fluor 488, 568, or 647 (Invitrogen) were used for immunoﬂ  uo  res-
cence. Images were acquired at room temperature using confocal micros-
copy (Nikon C1si with EZC1 acquisition software; Nikon) with Plan Apo 
10  ×   0.45 NA air, Plan Apo 20  ×   0.75 NA air, and Plan Apo 60  ×   1.40 NA 
oil objective lenses (Nikon). Colocalization with EC markers was measured 
using MetaMorph 7 (MDS Analytical Technologies). 
  Statistical analysis 
  Graphs are presented as mean   ±   SEM, with statistical signiﬁ  cance deter-
mined from a two-tailed Student  ’  s   t   test using      = 0.05 and P   <   0.05. 
  Online supplemental material 
  Fig. S1 provides the chemical structure and kinase proﬁ  le for the NVP-
TAC544 FAK inhibitor. Fig. S2 reveals the dose response of FAK inhibitors 
on FAK and Pyk2 tyrosine phosphorylation. Fig. S3 offers validation of the 
Pyk2 shRNA. Online supplemental material is available at http://www
.jcb.org/cgi/content/full/jcb.200710038/DC1. 
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reduce sprouting in aortic explants isolated from i-EC-FAK-KO 
mice (  Fig. 5 C  ). Thus, we have demonstrated using both genetic 
and pharmacological approaches that increased Pyk2 expres-
sion and kinase activity compensate for the loss of FAK within 
i-EC-FAK-KO mice during angiogenesis. These fi  ndings reveal 
that Pyk2, typically involved in hematopoietic signaling, can 
adapt to assume the function of FAK within ECs to preserve the 
angiogenic response in vivo. 
  Conclusions 
  We have demonstrated that although normal ECs express low 
levels of Pyk2, increased Pyk2 expression and activity occurs 
upon loss of FAK both in i-EC-FAK-KO mice and in cultured 
ECs treated with FAK shRNA (summarized in   Fig. 5 D  ). In cells 
with endogenous Pyk2, Pyk2 activity dose-dependently increases 
upon a 1-h treatment with pharmacological FAK inhibitors 
(  Figs. 3 F  , S1 C, and S2). Our fi  ndings support the hypothesis that 
ECs have the capacity to use Pyk2 signaling, but Pyk2 may be 
suppressed by FAK under normal conditions. Accordingly, the 
mechanism by which Pyk2 is up-regulated after FAK blockade 
warrants further investigation. We recently reported that Pyk2 
expression is elevated in primary mouse and human fi  broblasts 
upon FAK silencing and linked to enhanced p190RhoGEF ex-
pression leading to deregulated RhoA activation, elevated focal 
adhesion formation, and enhanced cell proliferation (  Lim et al., 
2008  ). Future work will reveal whether fi  broblasts, ECs, or even 
carcinoma cells may share similar pathways of FAK/Pyk2 regu-
lation and how these systems may contribute to the angiogenic 
response during cancer. This is especially relevant to the further 
development of dual FAK/Pyk2 inhibitors as anticancer or, po-
tentially, antiangiogenic drugs. 
  Materials and methods 
  Mice 
  All mice were maintained on a C57BL6 background. Floxed FAK mice 
containing two loxP sites ﬂ  anking exon 3 of the FAK gene (  Shen et al., 
2005  ) were crossed with mice harboring tamoxifen-inducible Cre-ER(T) 
driven by the 5     endothelial enhancer of the stem cell leukemia locus (pro-
vided by C.G. Begley, University of Western Australia, Perth, Australia; 
  Gothert et al., 2004  ). Age-matched littermates of FAK ﬂ  /ﬂ  ;Cre(+) and FAK 
ﬂ  /ﬂ  ;Cre(    ) mice were treated with 2 mg tamoxifen (Sigma-Aldrich) every 
2 d for 2 wk to generate WT mice (tamoxifen-treated mice with no Cre ex-
pression) and i-EC-FAK-KO mice (tamoxifen-induced EC-speciﬁ   c Cre ex-
pression and FAK deletion). 
  Inhibitors and shRNA 
  The cyclic RGD-fK peptide that binds integrin     v    3 with high potency and se-
lectivity was synthesized as described previously (  Dai et al., 2000  ). The FAK 
inhibitor NVP-TAC544 (  Garcia-Echevarria et al., 2004, 2005  ) provided by 
T. Honda (Novartis, Tsukuba, Ibaraki, Japan) was solubilized in Cremophore 
DL/DMSO/ethanol (1:1:1) and injected i.p. with 40 mg/kg daily (    850 nM). 
The dual FAK/Pyk2 inhibitor PF-271 (  Roberts et al., 2008  ) was synthesized 
according to available methods (  Kath and Luzzio, 2004  ;   Kath et al., 2005  ). 
The FAK inhibitor PF-228 (  Slack-Davis et al., 2007  ) was provided by 
W.G. Roberts (Pﬁ  zer, Groton, CT). Both inhibitors were solubilized in DMSO 
at 1 mM. Lentiviral expression of scramble control, FAK, and Pyk2 shRNA has 
been described previously (  Schlaepfer et al., 2007  ). 
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